Janux Therapeutics, Inc.

Equities

JANX

US47103J1051

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-05 pm EDT 5-day change 1st Jan Change
39.9 USD +3.64% Intraday chart for Janux Therapeutics, Inc. -1.09% +271.85%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell Small Cap Comp Value Index CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000 Value Index CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000E Index CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell Microcap Index CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 2500 Value Index CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 2000 Value Index CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell Microcap Growth Index CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000E Growth Index CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell Microcap Value Index CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000E Value Index CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) added to S&P Biotechnology Select Industry Index CI
Janux Therapeutics Insider Sold Shares Worth $45,043,975, According to a Recent SEC Filing MT
Janux Therapeutics Insider Sold Shares Worth $82,125,000, According to a Recent SEC Filing MT
Scotiabank Starts Janux Therapeutics With Sector Perform Rating MT
Certain Pre Funded Warrants of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024. CI
Certain Stock Options of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024. CI
Certain Common Stock of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024. CI
Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating MT
Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
JonesTrading Starts Janux Therapeutics With Buy Rating, $70 Price Target MT
Sector Update: Health Care Stocks Slipping Late Afternoon MT
Sector Update: Health Care MT
Janux Therapeutics Said to be Considering Sale MT
Janux Therapeutics Considering Options, Including Sale, Bloomberg Reports MT
Janux Therapeutics Reportedly Weighs Possible Sale CI
Chart Janux Therapeutics, Inc.
More charts
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
39.9 USD
Average target price
63.12 USD
Spread / Average Target
+58.21%
Consensus
  1. Stock Market
  2. Equities
  3. JANX Stock
  4. News Janux Therapeutics, Inc.
  5. Sector Update: Health Care Stocks Ease Late Afternoon